ARCHIVES

Rituximab Prolonged Survival Of CLL In Phase III Study

This article is from The Cancer Letter archive.

Vol. 33 No. 9 | September 24, 2010

Download PDF Visit The Full Archive

Related Articles

DeVita Considers Alternatives to Recommendation Of NCAB On Organ Systems Coordinating Center

June 1, 1984

Adding Topotecan To Standard Treatment Doesn’t Improve Progression-Free Survival

October 29, 2010

Upton Says NCI Must Take “Vigorous Role” In Prevention

February 3, 1978

In Brief: Rall Says He’ll Return Money To NCI If There Isn’t Any Left; OMB Releases 28 Positions For NTP

February 1, 1980

New ACS Awards Total $18.4 Million

February 23, 1979

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003